These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 23107836)

  • 1. Bevacizumab-containing chemotherapy is safe in patients with unresectable metastatic colorectal cancer and a synchronous asymptomatic primary tumor.
    Cetin B; Kaplan MA; Berk V; Tufan G; Benekli M; Isikdogan A; Ozkan M; Coskun U; Buyukberber S
    Jpn J Clin Oncol; 2013 Jan; 43(1):28-32. PubMed ID: 23107836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perioperative chemotherapy with or without bevacizumab in patients with metastatic colorectal cancer undergoing liver resection.
    Constantinidou A; Cunningham D; Shurmahi F; Asghar U; Barbachano Y; Khan A; Mudan S; Rao S; Chau I
    Clin Colorectal Cancer; 2013 Mar; 12(1):15-22. PubMed ID: 23021126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab efficacy in metastatic colorectal cancer is dependent on primary tumor resection.
    Ghiringhelli F; Bichard D; Limat S; Lorgis V; Vincent J; Borg C; Berthou J; Orry D; Ortega-Deballon P; Lakkis Z; Facy O; Heyd B; Rat P; Nerich V; Ladoire S
    Ann Surg Oncol; 2014 May; 21(5):1632-40. PubMed ID: 24419756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study.
    Bennouna J; Borg C; Delord JP; Husseini F; Trillet-Lenoir V; Faroux R; François E; Ychou M; Goldwasser F; Bouché O; Senellart H; Kraemer S; Douillard JY
    Clin Colorectal Cancer; 2012 Mar; 11(1):38-44. PubMed ID: 21803002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preoperative treatment with bevacizumab in combination with chemotherapy in patients with unresectable metastatic colorectal carcinoma.
    Figueras J; Lopez-Ben S; Alsina M; Soriano J; Hernandez-Yagüe X; Albiol M; Guardeño R; Codina-Barreras A; Queralt B
    Clin Transl Oncol; 2013 Jun; 15(6):460-6. PubMed ID: 23143951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of metastatic colorectal cancer with or without bevacizumab: can the neutrophil/lymphocyte ratio predict the efficiency of bevacizumab?
    Dirican A; Varol U; Kucukzeybek Y; Alacacioglu A; Erten C; Somali I; Can A; Demir L; Bayoglu IV; Akyol M; Yildiz Y; Koyuncu B; Coban E; Tarhan MO
    Asian Pac J Cancer Prev; 2014; 15(12):4781-6. PubMed ID: 24998541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer.
    Degirmenci M; Karaca B; Gorumlu G; Durusoy R; Demir Piskin G; Bozkurt MT; Cirak Y; Tunali D; Karabulut B; Sanli UA; Uslu R
    Med Oncol; 2010 Sep; 27(3):585-91. PubMed ID: 19526201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to chemotherapy in metastatic colorectal cancer after exposure to oxaliplatin in the adjuvant setting.
    Moreau LC; Rajan R; Thirlwell MP; Alcindor T
    Anticancer Res; 2013 Apr; 33(4):1765-8. PubMed ID: 23564831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant therapy for stage II and III colorectal cancer.
    de Gramont A; Tournigand C; André T; Larsen AK; Louvet C
    Semin Oncol; 2007 Apr; 34(2 Suppl 1):S37-40. PubMed ID: 17449351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Evaluation of bevacizumab combined with irinotecan-based regimen as the first-line treatment for patients with metastatic colorectal cancer].
    Lin L; Xu JM; Wang Y; Ge FJ; Liu LJ; Zhao CH; Li SS; Liu JZ; Li ZQ
    Zhonghua Zhong Liu Za Zhi; 2010 Oct; 32(10):786-90. PubMed ID: 21163073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary mFOLFOX6 plus bevacizumab without resection of the primary tumor for patients presenting with surgically unresectable metastatic colon cancer and an intact asymptomatic colon cancer: definitive analysis of NSABP trial C-10.
    McCahill LE; Yothers G; Sharif S; Petrelli NJ; Lai LL; Bechar N; Giguere JK; Dakhil SR; Fehrenbacher L; Lopa SH; Wagman LD; O'Connell MJ; Wolmark N
    J Clin Oncol; 2012 Sep; 30(26):3223-8. PubMed ID: 22869888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of primary tumor resection in colorectal cancer patients with synchronous unresectable metastasis.
    Kim MS; Chung M; Ahn JB; Kim CW; Cho MS; Shin SJ; Baek SJ; Hur H; Min BS; Baik SH; Kim NK
    J Surg Oncol; 2014 Aug; 110(2):214-21. PubMed ID: 24668581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of liver metastasectomies in patients with metastatic colorectal cancer treated with FIr-B/FOx triplet chemotherapy plus bevacizumab.
    Bruera G; Cannita K; Giuliante F; Lanfiuti Baldi P; Vicentini R; Marchetti P; Nuzzo G; Antonucci A; Ficorella C; Ricevuto E
    Clin Colorectal Cancer; 2012 Jun; 11(2):119-26. PubMed ID: 22206922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficacy and safety of bevacizumab (BEV) plus chemotherapeutic agents in the treatment of metastatic colorectal cancer, mCRC].
    Guo X; Liu TS; Yu YY; Zhou YH; Chen Y; Zhuang RY; Cui YH
    Zhonghua Zhong Liu Za Zhi; 2013 Aug; 35(8):604-7. PubMed ID: 24314219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficacy of cetuximab combined with chemotherapy for patients with advanced colorectal cancer and unclear K-ras status].
    Guo GF; Xia LP; Qiu HJ; Xu RH; Zhang B; Jiang WQ; Zhou FF; Wang F
    Zhonghua Zhong Liu Za Zhi; 2010 Oct; 32(10):777-81. PubMed ID: 21163071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse events associated with bevacizumab and chemotherapy in older patients with metastatic colorectal cancer.
    Shankaran V; Mummy D; Koepl L; Blough D; Yim YM; Yu E; Ramsey S
    Clin Colorectal Cancer; 2013 Sep; 12(3):204-213.e1. PubMed ID: 23276520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A case of locally advanced colorectal cancer with abscess responding to 5-fluorouracil, leucovorin, and oxaliplatin plus bevacizumab].
    Kuwabara H; Watanabe S; Liu B; Mitsuoka A; Sanada T; Nakajima K; Goseki N
    Gan To Kagaku Ryoho; 2013 Nov; 40(12):2032-4. PubMed ID: 24394003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bevacizumab in the treatment of colorectal cancer.
    Marshall JL
    Clin Adv Hematol Oncol; 2007 Jan; 5(1 Suppl 1):8-9. PubMed ID: 17491585
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study).
    Ducreux M; Adenis A; Pignon JP; François E; Chauffert B; Ichanté JL; Boucher E; Ychou M; Pierga JY; Montoto-Grillot C; Conroy T
    Eur J Cancer; 2013 Apr; 49(6):1236-45. PubMed ID: 23352604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preoperative chemotherapy does not increase morbidity or mortality of hepatic resection for colorectal cancer metastases.
    Scoggins CR; Campbell ML; Landry CS; Slomiany BA; Woodall CE; McMasters KM; Martin RC
    Ann Surg Oncol; 2009 Jan; 16(1):35-41. PubMed ID: 18987915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.